Market closed
Dyne Therapeutics/$DYN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Dyne Therapeutics
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
Ticker
$DYN
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
191
ISIN
US26818M1080
Website
DYN Metrics
BasicAdvanced
$1.3B
-
-$3.62
-
-
Price and volume
Market cap
$1.3B
52-week high
$47.45
52-week low
$6.36
Average daily volume
3M
Financial strength
Current ratio
20.35
Quick ratio
19.996
Long term debt to equity
2.723
Total debt to equity
3.487
Management effectiveness
Return on assets (TTM)
-39.92%
Return on equity (TTM)
-64.01%
Valuation
Price to book
1.92
Price to tangible book (TTM)
1.92
Price to free cash flow (TTM)
-3.546
Growth
Earnings per share change (TTM)
-7.31%
3-year earnings per share growth (CAGR)
5.22%
What the Analysts think about DYN
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Dyne Therapeutics stock.
DYN Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
DYN Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
DYN News
AllArticlesVideos
Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
GlobeNewsWire·2 days ago
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
GlobeNewsWire·2 weeks ago
Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Dyne Therapeutics stock?
Dyne Therapeutics (DYN) has a market cap of $1.3B as of May 10, 2025.
What is the P/E ratio for Dyne Therapeutics stock?
The price to earnings (P/E) ratio for Dyne Therapeutics (DYN) stock is 0 as of May 10, 2025.
Does Dyne Therapeutics stock pay dividends?
No, Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders as of May 10, 2025.
When is the next Dyne Therapeutics dividend payment date?
Dyne Therapeutics (DYN) stock does not pay dividends to its shareholders.
What is the beta indicator for Dyne Therapeutics?
Dyne Therapeutics (DYN) does not currently have a Beta indicator.